Skip to main content
Erschienen in: Journal of Nephrology 9/2022

25.08.2022 | COVID-19 | From Distant Places

Acute kidney injury in critically ill patients with COVID-19: prevalence, risk factors and mortality in eastern Morocco

verfasst von: Essaad Ounci, Sara Boukabous, Houssam Bkiyar, Naima Abda, Yassamine Bentata, Brahim Housni

Erschienen in: Journal of Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Acute kidney injury (AKI) is commonly seen in critically ill hospitalized patients with COVID-19 and its incidence reaches 60% in this setting. The aim of this work was to determine the prevalence, characteristics, risk factors and mortality of AKI in patients admitted to the intensive care unit (ICU) for COVID-19.

Patients and methods

This observational retrospective case series was conducted between February 1, 2020 and December 31, 2020 at the ICU of the university hospital Mohammed VI of Oujda, Morocco. all COVID-19 patients hospitalized in the ICU with acute respiratory failure were included. AKI was defined and classified into three stages using the KDIGO criteria 2012. We excluded patients with end-stage kidney disease and those who were under 18 years old.

Results

Six hundred adult patients were included and 65.5% of them were men. Sixty patients had minimal lung damage (< 25%), 105 patients had mild lung damage (25–50%), 186 had severe lung damage (50–75%) and 193 patients had very severe lung damage (> 75%). A total of 210 patients (35%) developed AKI, of whom 78 (37.2%) had mild AKI (stage 1) and 132 (62.8%) severe AKI (stages 2 and 3). Patients in the severe and mild AKI groups had a higher rate of comorbidities, especially hypertension (mild AKI [46.2%] vs. severe AKI [36.4%] vs. no AKI [27.4%], p = 0.002) and diabetes (mild AKI [52.6%] vs. severe AKI [33.3%] vs. no AKI [26.4%], p < 0.001). During hospitalization, 23.3% of patients with AKI received kidney replacement therapy. In-hospital mortality was observed in 51.3% for mild AKI, 55.3% for severe AKI and 21% in patients who did not have AKI (p < 0.001).

Conclusion

Our findings revealed that not only severe AKI, but also mild AKI was correlated to in-hospital mortality. Whatever the severity of the kidney impairment, it remains a major prognostic element.
Literatur
1.
Zurück zum Zitat Yang X, Jin Y, Li R et al (2020) Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta- analysis. Crit Care 24:356CrossRefPubMedPubMedCentral Yang X, Jin Y, Li R et al (2020) Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta- analysis. Crit Care 24:356CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Nimkar A, Naaraayan A, Hasan A, Pant S, Durdevic M, Suarez CN, Jesmajian S. Incidence and risk factors for acute kidney injury and its effect on mortality in patients hospitalized from COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):687–95. Nimkar A, Naaraayan A, Hasan A, Pant S, Durdevic M, Suarez CN, Jesmajian S. Incidence and risk factors for acute kidney injury and its effect on mortality in patients hospitalized from COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):687–95.
3.
Zurück zum Zitat Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, Paranjpe I, Richter F, Nadkarni GN, Lala A et al (2021) Mount Sinai COVID Informatics Center (MSCIC). AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32:151–60. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, Paranjpe I, Richter F, Nadkarni GN, Lala A et al (2021) Mount Sinai COVID Informatics Center (MSCIC). AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32:151–60.
4.
Zurück zum Zitat STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383:240–51. STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383:240–51.
5.
Zurück zum Zitat Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–13. Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–13.
6.
Zurück zum Zitat Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al; and the Northwell COVID-19 Research Consortium: presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al; and the Northwell COVID-19 Research Consortium: presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.
7.
Zurück zum Zitat Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD, Abate M et al (2020) Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98:209–218CrossRefPubMedPubMedCentral Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD, Abate M et al (2020) Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98:209–218CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gupta S, Hayek SS, Wang W et al (2020) Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 180(11):1436–1447CrossRefPubMed Gupta S, Hayek SS, Wang W et al (2020) Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 180(11):1436–1447CrossRefPubMed
9.
Zurück zum Zitat Gaston JP, Alicia M‐A, Evelyn H, Miquel B, Luis FQ, Guido MR, Jordi M, Esteban P. Severe acute kidney injury in critically ill COVID‐19 patients. J Nephrol. 2021;34(2):285–93. Gaston JP, Alicia M‐A, Evelyn H, Miquel B, Luis FQ, Guido MR, Jordi M, Esteban P. Severe acute kidney injury in critically ill COVID‐19 patients. J Nephrol. 2021;34(2):285–93.
Metadaten
Titel
Acute kidney injury in critically ill patients with COVID-19: prevalence, risk factors and mortality in eastern Morocco
verfasst von
Essaad Ounci
Sara Boukabous
Houssam Bkiyar
Naima Abda
Yassamine Bentata
Brahim Housni
Publikationsdatum
25.08.2022
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Journal of Nephrology / Ausgabe 9/2022
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-022-01401-1

Weitere Artikel der Ausgabe 9/2022

Journal of Nephrology 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.